MD Anderson study shows FGL2 protein may be an effective target for glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
Findings from the preclinical study led by Shulin Li, Ph.D., professor of Pediatrics, and Amy Heimberger, M.D., professor of Neurosurgery, were published in the Jan. 25 online...
Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to...
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
MD Anderson Cancer Center and Ascentage Pharma announce strategic alliance in cancer drug development
The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies.
The alliance is aimed at developing novel cancer therapeutics based upon Ascentage’s proprietary Protein-Protein Interaction drug discovery technology platform. MD Anderson’s leukemia team will join in efforts to advance...
